Hadasit Bio-Holdings

Press Releases

Allowance of Patent in Israel - ProtAb Ltd

Apr. 14, 2015

HBL – Hadasit Bio-Holdings Ltd.

(the “Company”)

April 14, 2015

 

 

To                                            To

Securities Authority                Tel Aviv Stock Exchange Ltd.

www.isa.gov.il                        www.tase.co.il

 

Re: Allowance of Patent in Israel - ProtAb Ltd

 

The Company is pleased to announce that ProtAb Ltd, which is held 69.54%by the Company (not fully diluted basis), (hereinafter: "ProtAb") received allowance of a patent in Israel titled:

ANTIBODIES DIRECTED AGAINST B CELL EPITOPE PEPTIDES COMPOSITIONS AND USES THEREOF (Israeli patent application No. 191165, which is a divisional application of the parent patent in Israel No. 142709) (the “Patent”).

The Patent is owned by Hadasit Medical Research Services and Development Ltd. (“Hadasit”), whereby according to an exclusive license agreement signed between ProtAb and Hadasit, ProtAb has an exclusive license to use and exploit this patent. 

The Patent covers antibodies against novel peptide sequences and the use of these antibodies for the treatment of patients with autoimmune and inflammatory diseases, and along with the parent patent covers protection of two parts: the peptide sequences and antibodies against these sequences.

The Patent term is until November 2019.

ProtAb is focused on the development of novel therapeutic agents for the treatment of Inflammatory Bowel Diseases (including Crohn’s disease and Ulcerative Colitis) and additional autoimmune diseases.  

 

 

 

Sincerely,

 

HBL – Hadasit Bio-Holdings Ltd.

By: Mrs. Tamar Kfir, CEO

 
 

Press Releases Archive